Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors
The Prostate · 2026-03 · 86 (4) · 428-439
DOI: 10.1002/pros.70100 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, online erschienen am 09.12.2025. Verfasst von Hyun-Kyung Ko und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Receptors, Androgen, Epithelial-Mesenchymal Transition, NAD, Prostatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: OHSU Prostate Cancer Program and NIH.
Abstract (Originalsprache)
Background
Metastatic prostate cancers are primarily treated by therapies targeting the androgen/androgen receptor (AR) signaling pathways. Despite the initial success, treatment resistance is almost universal, leading to disease progression and patient mortality. Currently, the molecular mechanism and vulnerability of treatment‐resistant prostate cancers are poorly understood. These knowledge gaps are major obstacles in improving treatment and patient survival. Recently, we used the single‐cell approach to establish a new anti‐androgen/AR resistant cell model, in which tumor cells had an AR‐low phenotype, expressing low levels of AR and AR‐target genes, and were resistant to androgen‐deprivation (ADT) and enzalutamide in vitro and in vivo.
Methods
We determined the transcriptome of the treatment‐resistant AR‐low cells with bulk RNA‐Seq, qRT‐PCR, and chromatin immunoprecipitation (ChIP)‐qPCR. We identified a metabolic vulnerability of the resistant cells with siRNA, plasmid‐based overexpression and metabolic assays. We next determined whether the vulnerability can be exploited by small molecule inhibitors to enhance enzalutamide with proliferation and colony formation assays and Incucyte‐based live cell imaging. We also determined the clinical relevance of the vulnerability with the prostate cancer TCGA data set.
Results
The AR‐low treatment resistant tumor cells had significantly different transcriptomes from the treatment‐sensitive counterparts, notably represented by the EMT‐high expression phenotype. The resistant cells were deficient in the expression of NAPRT, a rate determining enzyme in nicotinamide adenine dinucleotide (NAD+) biosynthesis, causing the resistant cells to be vulnerable to NAD+ biosynthesis inhibitors. Importantly, this vulnerability can be exploited to enhance enzalutamide efficacy in the castration sensitive setting as NAPRT‐low was phenotypically associated with EMT‐high and AR‐low in subpopulations of tumor cells and patient samples.
Conclusion
Our newly established treatment‐resistant cell model has the AR‐low/EMT‐high phenotype, which is clinically associated with enzalutamide resistance in patients. NAPRT‐deficiency (NAPRT‐low) can be a novel vulnerability associated with the AR‐low/EMT‐high phenotype and thus can be targeted by NAD+ inhibitors to improve enzalutamide efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
- Biostatistics Core, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
ORCID-Profile: Lina Gao
Förderung
- OHSU Prostate Cancer Program and NIH
Zitieren
APA
Ko, H. K., Foertsch, R. L., Shi, K., Pittsenbarger, J., Xue, C., Shi, K., Geng, H., Gao, L., & Qian, D. Z. (2026). Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors. The Prostate, 86(4), 428-439. https://doi.org/10.1002/pros.70100
Vancouver
Ko HK, Foertsch RL, Shi K, Pittsenbarger J, Xue C, Shi K, et al. Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors. The Prostate. 2026;86(4):428-439. doi:10.1002/pros.70100
BibTeX
@article{Ko2026,
author = {Ko, Hyun-Kyung and Foertsch, Rebecca L and Shi, Kasen and Pittsenbarger, Janét and Xue, Changhui and Shi, Kaiyo and Geng, Hao and Gao, Lina and Qian, David Z},
title = {Prostate Cancer Cells With the AR‐Low and EMT‐High Phenotype Are Vulnerable to NAD+ Synthesis Inhibitors},
journal = {The Prostate},
year = {2026},
volume = {86},
number = {4},
pages = {428--439},
doi = {10.1002/pros.70100}
}
EUVIMED